← Eichor
Condition: Myotonic Dystrophy Type 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myotonic Dystrophy Type 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Herombopag Treated T-DM1 Induced Platelet Reduction
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07257809Personalized Training for People With Rare Neuromuscular Disorders
NA · 5 location(s) · Oslo University Hospital · NCT06708468Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT07700225Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological R
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT06272799Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 · 13 location(s) · Dana-Farber Cancer Institute · NCT04620187Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07505342The United Kingdom National Registry for Myotonic Dystrophy
Phase N/A · 1 location(s) · Newcastle University · NCT04003363Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NA · 1 location(s) · Université de Sherbrooke · NCT06316778Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dys
Phase 1/Phase 2 · 20 location(s) · Dyne Therapeutics · NCT05481879The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Phase 3 · 7 location(s) · Lupin Ltd. · NCT06523400Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT06747884An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Phase 2 · 3 location(s) · PepGen Inc · NCT07220603Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Phase 3 · 21 location(s) · Dyne Therapeutics · NCT07486934Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Phase N/A · 17 location(s) · Virginia Commonwealth University · NCT03981575A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06830889A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Phase 2 · 8 location(s) · PepGen Inc · NCT06667453Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Phase 1/Phase 2 · 11 location(s) · Arrowhead Pharmaceuticals · NCT06138743Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07630389Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
Phase N/A · 1 location(s) · Shu Wang · NCT06693037Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Phase N/A · 1 location(s) · University of Rochester · NCT00082108JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06846437Study of ATX-01 in Participants With DM1
Phase 1/Phase 2 · 12 location(s) · ARTHEx Biotech S.L. · NCT06300307A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 3 · 70 location(s) · GeneQuantum Healthcare (Suzhou) Co., Ltd. · NCT07673029Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Phase 2/Phase 3 · 14 location(s) · AMO Pharma Limited · NCT05004129DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Phase N/A · 5 location(s) · Virginia Commonwealth University · NCT05224778A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Ge
Phase 1/Phase 2 · 9 location(s) · Sanofi · NCT06844214Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Phase N/A · 1 location(s) · Massachusetts General Hospital · NCT06075693Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05532813
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.